Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy |
| |
Authors: | Matthew D. Galsky Erin Moshier Susan Krege Chia-Chi Lin Noah Hahn Thorsten Ecke Guru Sonpavde Gregory Pond James Godbold William K. Oh Aristotle Bamias |
| |
Affiliation: | 1. The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY;2. Urologische Klinik, Alexianer Krefeld GmbH, Krefeld, Germany;3. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan;4. Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN;5. HELIOS Hospital, Bad Saarow, Germany;6. US Oncology Research, LLC, McKesson Specialty Health, The Woodlands, TX;7. University of Alabama Comprehensive Cancer Center, Birmingham, AL;8. McMaster University, Ontario, Canada;9. University of Athens, Athens, Greece;10. Hellenic Cooperative Oncology Group, Athens, Greece |
| |
Abstract: | BackgroundModels to predict the outcome of patients with metastatic urothelial cancer (UC), based on pretreatment variables, have previously been developed. However, patients often request “updated” prognostic estimates based upon their response to treatment.Patients and MethodsData were pooled from 317 patients enrolled in 8 trials evaluating first-line cisplatin-based chemotherapy in metastatic UC. Variables were combined in the Cox proportional hazards model to produce a nomogram to predict survival from the end of treatment. The nomogram was validated externally using data from a phase III trial.ResultsThe median survival from end of treatment was 10.65 months (95% confidence interval; 9.20–13.24); 69% of patients had died. Baseline and posttreatment variables were evaluated. Baseline performance status, baseline number of visceral metastatic sites, baseline white blood counts, and response to treatment were included in the final model. The nomogram achieved a bootstrap-corrected concordance index of 0.68. Upon external validation, the nomogram achieved a concordance index of 0.67.ConclusionsA model derived from pretreatment and posttreatment variables was constructed to predict survival from the completion of first-line chemotherapy in patients with metastatic UC. This model may be useful for patient counseling and for stratification of trials exploring “maintenance” therapy. |
| |
Keywords: | Urothelial cancer Metastatic Prognosis Nomogram Cisplatin Chemotherapy |
本文献已被 ScienceDirect 等数据库收录! |
|